The Impact of Incretin-Based Medications on Lipid Metabolism

Overview

Journal J Diabetes Res

Publisher Wiley

Specialty Endocrinology

Date 2022 Jan 10

PMID 35005028

Authors

Habib Yaribeygi

Mina Maleki

Alexandra E Butler

Tannaz Jamialahmadi

Amirhossein Sahebkar

Affiliations

Soon will be listed here.

Abstract

Pathophysiological pathways that are induced by chronic hyperglycemia negatively impact lipid metabolism. Thus, diabetes is commonly accompanied by varying degrees of dyslipidemia which is itself a major risk factor for further macro- and microvascular diabetes complications such as atherosclerosis and nephropathy. Therefore, normalizing lipid metabolism is an attractive goal for therapy in patients with diabetes. Incretin-based medications are a novel group of antidiabetic agents with potent hypoglycemic effects. While the impact of incretins on glucose metabolism is clear, recent evidence indicates their positive modulatory roles on various aspects of lipid metabolism. Therefore, incretins may offer additional beneficial effects beyond that of glucose normalization. In the current review, how these antidiabetic medications can regulate lipid homeostasis and the possible cellular pathways involved are discussed, incorporating related clinical evidence about incretin effects on lipid homeostasis.

Citing Articles

Interplay of fatty acids, insulin and exercise in vascular health.

Anderson K, Liu J, Liu Z Lipids Health Dis. 2025; 24(1):4.

PMID: 39773723 PMC: 11706162. DOI: 10.1186/s12944-024-02421-5.

Adipocyte inflammation is the primary driver of hepatic insulin resistance in a human iPSC-based microphysiological system.

Qi L, Groeger M, Sharma A, Goswami I, Chen E, Zhong F Nat Commun. 2024; 15(1):7991.

PMID: 39266553 PMC: 11393072. DOI: 10.1038/s41467-024-52258-w.

Lipid regulation of the glucagon receptor family.

Oqua A, Manchanda Y, McGlone E, Jones B, Rouse S, Tomas A J Endocrinol. 2024; 261(3).

PMID: 38614123 PMC: 11103681. DOI: 10.1530/JOE-23-0335.

Anti-inflammatory benefits of semaglutide: State of the art.

Yaribeygi H, Maleki M, Jamialahmadi T, Sahebkar A J Clin Transl Endocrinol. 2024; 36:100340.

PMID: 38576822 PMC: 10992717. DOI: 10.1016/j.jcte.2024.100340.

Transforming Diabetes Care: The Molecular Pathways through Which GLP1-RAs Impact the Kidneys in Diabetic Kidney Disease.

Rroji M, Spasovski G Biomedicines. 2024; 12(3).

PMID: 38540270 PMC: 10967743. DOI: 10.3390/biomedicines12030657.

References

Athyros V, Doumas M, Imprialos K, Stavropoulos K, Georgianou E, Katsimardou A . Diabetes and lipid metabolism. Hormones (Athens). 2018; 17(1):61-67. DOI: 10.1007/s42000-018-0014-8. View

Yaribeygi H, Maleki M, Sathyapalan T, Jamialahmadi T, Sahebkar A . Anti-inflammatory potentials of incretin-based therapies used in the management of diabetes. Life Sci. 2019; 241:117152. DOI: 10.1016/j.lfs.2019.117152. View

Xu F, Lin B, Zheng X, Chen Z, Cao H, Xu H . GLP-1 receptor agonist promotes brown remodelling in mouse white adipose tissue through SIRT1. Diabetologia. 2016; 59(5):1059-69. DOI: 10.1007/s00125-016-3896-5. View

Lando H, Alattar M, Dua A . Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting. Endocr Pract. 2012; 18(4):472-7. DOI: 10.4158/EP11290.OR. View

Wang Y, Viscarra J, Kim S, Sul H . Transcriptional regulation of hepatic lipogenesis. Nat Rev Mol Cell Biol. 2015; 16(11):678-89. PMC: 4884795. DOI: 10.1038/nrm4074. View

Ideta T, Shirakami Y, Miyazaki T, Kochi T, Sakai H, Moriwaki H . The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice. Int J Mol Sci. 2015; 16(12):29207-18. PMC: 4691103. DOI: 10.3390/ijms161226156. View

Luo J, Yang H, Song B . Mechanisms and regulation of cholesterol homeostasis. Nat Rev Mol Cell Biol. 2019; 21(4):225-245. DOI: 10.1038/s41580-019-0190-7. View

Ursini F, Maiorino M . Lipid peroxidation and ferroptosis: The role of GSH and GPx4. Free Radic Biol Med. 2020; 152:175-185. DOI: 10.1016/j.freeradbiomed.2020.02.027. View

Wang X, Liu J, Li C, Zhao M, Liu L, Guan Q . Impaired secretion of active GLP-1 in patients with hypertriglyceridaemia: A novel lipotoxicity paradigm?. Diabetes Metab Res Rev. 2017; 34(2). DOI: 10.1002/dmrr.2964. View

10.

Hong J, Kim D, Lee M . Glucolipotoxicity and GLP-1 secretion. BMJ Open Diabetes Res Care. 2021; 9(1). PMC: 7908300. DOI: 10.1136/bmjdrc-2020-001905. View

11.

Laliotis G, Bizelis I, Rogdakis E . Comparative Approach of the de novo Fatty Acid Synthesis (Lipogenesis) between Ruminant and Non Ruminant Mammalian Species: From Biochemical Level to the Main Regulatory Lipogenic Genes. Curr Genomics. 2010; 11(3):168-83. PMC: 2878982. DOI: 10.2174/138920210791110960. View

12.

Hsieh J, Trajcevski K, Farr S, Baker C, Lake E, Taher J . Glucagon-Like Peptide 2 (GLP-2) Stimulates Postprandial Chylomicron Production and Postabsorptive Release of Intestinal Triglyceride Storage Pools via Induction of Nitric Oxide Signaling in Male Hamsters and Mice. Endocrinology. 2015; 156(10):3538-47. DOI: 10.1210/EN.2015-1110. View

13.

Hasegawa Y, Hori M, Nakagami T, Harada-Shiba M, Uchigata Y . Glucagon-like peptide-1 receptor agonists reduced the low-density lipoprotein cholesterol in Japanese patients with type 2 diabetes mellitus treated with statins. J Clin Lipidol. 2017; 12(1):62-69.e1. DOI: 10.1016/j.jacl.2017.11.006. View

14.

Ben-Shlomo S, Zvibel I, Shnell M, Shlomai A, Chepurko E, Halpern Z . Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase. J Hepatol. 2010; 54(6):1214-23. DOI: 10.1016/j.jhep.2010.09.032. View

15.

Penno G, Solini A, Zoppini G, Fondelli C, Trevisan R, Vedovato M . Hypertriglyceridemia Is Independently Associated with Renal, but Not Retinal Complications in Subjects with Type 2 Diabetes: A Cross-Sectional Analysis of the Renal Insufficiency And Cardiovascular Events (RIACE) Italian Multicenter Study. PLoS One. 2015; 10(5):e0125512. PMC: 4420503. DOI: 10.1371/journal.pone.0125512. View

16.

Zhao X, Feng D, Wang Q, Abdulla A, Xie X, Zhou J . Regulation of lipogenesis by cyclin-dependent kinase 8-mediated control of SREBP-1. J Clin Invest. 2012; 122(7):2417-27. PMC: 3386818. DOI: 10.1172/JCI61462. View

17.

Ducheix S, Lobaccaro J, Martin P, Guillou H . Liver X Receptor: an oxysterol sensor and a major player in the control of lipogenesis. Chem Phys Lipids. 2011; 164(6):500-14. DOI: 10.1016/j.chemphyslip.2011.06.004. View

18.

Zillessen P, Celner J, Kretschmann A, Pfeifer A, Racke K, Mayer P . Metabolic role of dipeptidyl peptidase 4 (DPP4) in primary human (pre)adipocytes. Sci Rep. 2016; 6:23074. PMC: 4794806. DOI: 10.1038/srep23074. View

19.

Patel V, Joharapurkar A, Dhanesha N, Kshirsagar S, Detroja J, Patel K . Combination of omeprazole with GLP-1 agonist therapy improves insulin sensitivity and antioxidant activity in liver in type 1 diabetic mice. Pharmacol Rep. 2013; 65(4):927-36. DOI: 10.1016/s1734-1140(13)71074-0. View

20.

Ko C, Qu J, Black D, Tso P . Regulation of intestinal lipid metabolism: current concepts and relevance to disease. Nat Rev Gastroenterol Hepatol. 2020; 17(3):169-183. DOI: 10.1038/s41575-019-0250-7. View